Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

NCT02784483 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Based on FDA requirements

Conditions

Asymptomatic Myeloma

Interventions

DRUG: Atezolizumab (1200mg via IV infusion)

Sponsor

Yale University